NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-CA-18-046 from the NIH Guide for Grants and Contracts
Notice NOT-CA-18-042 from the NIH Guide for Grants and Contracts
Notice NOT-CA-18-043 from the NIH Guide for Grants and Contracts
Notice NOT-OD-18-131 from the NIH Guide for Grants and Contracts
Notice NOT-CA-18-039 from the NIH Guide for Grants and Contracts
Notice NOT-CA-18-038 from the NIH Guide for Grants and Contracts
Notice NOT-HS-18-005 from the NIH Guide for Grants and Contracts
Notice NOT-HL-17-571 from the NIH Guide for Grants and Contracts
Notice NOT-GM-18-015 from the NIH Guide for Grants and Contracts
Notice NOT-OD-18-128 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AA-18-009 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite cooperative agreement applications for research that advances promising compounds thorough the drug development pipeline for the treatment of Alcohol Use Disorder (AUD). NIAAA is seeking applications for medications development research projects from both for-profit and not-for-profit entities, including academic institutions, pharmaceutical and biotechnology companies, private and public foundations, small businesses not eligible for the SBIR/STTR program and single entities able to demonstrate significant resource commitment to the proposed project. A resource commitment from a single entity could, for example, consist of salary support for key personnel or production and formulation of clinical trial material. The aim of this FOA is to move candidate compounds through Investigational New Drug (IND) requirements, Phase 1 human safety, tolerability, and dosing studies, and Phase 2 human laboratory and proof-of-concept trials. Within these phases of drug development, each proposed project should have a defined entry and exit point. Finally, this FOA will not support animal studies to prove efficacy of the candidate compound unless required by the Food and Drug Administration or peer review. Applicants are strongly encouraged to contact the NIAAA Division of Medications Development Staff prior to submitting to this FOA.
Funding Opportunity PA-18-569 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages R01 grant applications to conduct rigorous health services and economic research to maximize the delivery of efficient, high-quality drug, tobacco, and alcohol prevention, treatment, and recovery support services. Examples of such research include: (1) clinical quality improvement; (2) quality improvement in services organization and management; (3) implementation research; (4) economic and cost studies; and (5) development or improvement of research methodology, analytic approaches, and measurement instrumentation used in the study of drug, alcohol, and tobacco prevention, treatment, and recovery services.
Notice NOT-DK-18-009 from the NIH Guide for Grants and Contracts
Notice NOT-DA-18-001 from the NIH Guide for Grants and Contracts
Notice NOT-DE-18-003 from the NIH Guide for Grants and Contracts
Notice NOT-DE-18-004 from the NIH Guide for Grants and Contracts
Notice NOT-TR-18-016 from the NIH Guide for Grants and Contracts
Notice NOT-TR-18-013 from the NIH Guide for Grants and Contracts
Notice NOT-HL-18-581 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-18-583 from the NIH Guide for Grants and Contracts. As part of the Gabriella Miller Kids First Pediatric Research Program (Kids First), the NIH invites applications to use submit samples from pediatric cohorts for whole genome sequencing at a Kids First-supported sequencing center. Applicants are encouraged to propose sequencing of existing pediatric cancer cohorts to elucidate the genetic contribution to childhood cancers, or to expand the range of disorders included within the Kids First Data Resource to investigate the genetic etiology of structural birth defects. Whole genome, exome, and transcriptome sequencing are available for tumor or affected tissue when justified. These data will become part of the Gabriella Miller Kids First Pediatric Data Resource (Kids First Data Resource) for the pediatric research community.